H

HDAC / EGFR / Her2 inhibitor CUDC-101

A multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal … [Read more...]

HDAC inhibitor

A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of cancer. Also called … [Read more...]

HDAC inhibitor CHR-2845

A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of … [Read more...]

HDAC inhibitor CHR-3996

An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor … [Read more...]

HDAC inhibitor CRA-024781

A novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CRA-024781 inhibits … [Read more...]

HDAC inhibitor JNJ-26481585

An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor … [Read more...]

HDAC inhibitor PCI-24781

A broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor PCI-24781 inhibits … [Read more...]

HDAC inhibitor SB939

An orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. HDAC inhibitor SB939 inhibits HDACs, which … [Read more...]

HDAC inhibitor SNDX-275

A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of … [Read more...]

HDM2 antagonist JNJ-26854165

An orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. HDM2 antagonist JNJ-26854165 inhibits the binding of theHDM2 … [Read more...]